Sayaka Nagata

Dr. Sayaka Nagata


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2017 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
SNSayaka Nagata
Sayaka Nagata
MYMotoo Yamasaki
Motoo Yamasaki
KKKazuo Kitamura
Kazuo Kitamura

1 November 2019 in Peptides
Verified
Journal Article
Closed access
SNSayaka Nagata
Sayaka Nagata
MYMotoo Yamasaki
Motoo Yamasaki
KKKazuo Kitamura
Kazuo Kitamura

19 July 2022 in Biology
Verified
Journal Article
Open access
PDF file
SNSayaka Nagata
Sayaka Nagata
MYMotoo Yamasaki
Motoo Yamasaki
NKNobuko Kuroishi
Nobuko Kuroishi
KKKazuo Kitamura
Kazuo Kitamura
(1) Background: Human adrenomedullin (hAM) is a hypotensive peptide hormone that exerts powerful anti-inflammatory effects. AM also had therapeutic effects in various animal experimental models of disease. However, treatment required continuous administration as the half-life of native AM is short in blood. To resolve this, we developed four human IgG1 and IgG4 Fc-fusion proteins containing full-length hAM or hAM residues 6-52. (2) Methods: We used mammalian cells to produce recombinant Fc-AM derivatives and tested the pharmacokinetics and biological activity of Fc-AM. (3) Results: We developed four Fc-fusion AMs (Fc-AM), which are long-acting AM derivatives in mammalian cells. Fc-AM had a prolonged half-life in blood and retained its ability to bind to the AM1 receptor. Fc-AM (6-52) induced higher cAMP levels for the receptor than Fc-AM. After the administration of IgG1-AM (6-52) or IgG4-AM (6-52) to rats, tissue transfer to the kidney and small intestine was observed. In addition, treatment with IgG4-AM (6-52) inhibited blood pressure increase in spontaneously hypertensive rats. (4) Conclusions: Fc-AM produced from mammalian cells can be easily prepared and might be an effective novel therapeutic agent.

8 May 2021 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
NKNobuko Kuroishi
Nobuko Kuroishi
SNSayaka Nagata
Sayaka Nagata
EAEmiko Akashi
Emiko Akashi
SAShinya Ashizuka
Shinya Ashizuka
JKJohji Kato
Johji Kato
KKKazuo Kitamura
Kazuo Kitamura
Adrenomedullin is a biologically active peptide with multiple functions. Here, we have developed a novel human serum albumin-adrenomedullin (HSA-AM) conjugate, which was synthesized by the covalent attachment of a maleimide derivative of adrenomedullin to the 34th cysteine residue of HSA via a linker. Denaturing gel electrophoresis and western blotting for HSA-AM yielded a single band with adrenomedullin immunoreactivity at the position corresponding to a molecular weight (MW) of 73 kDa. Following gel-filtration chromatography, the purified HSA-AM showed a single main peak corresponding with an MW of 73 kDa, indicating that HSA-AM is a monomer. Both adrenomedullin and HSA-AM stimulated the intracellular accumulation of cyclic AMP (cAMP) in HEK-293 cells stably expressing the adrenomedullin 1 receptor. The pEC50 values for adrenomedullin and HSA-AM were 8.660 and 7.208 (equivalent to 2.19 and 61.9 nM as EC50), respectively. The bioavailability of HSA-AM compared with that of adrenomedullin was much improved after subcutaneous administration in the rat, which was probably due to the superior resistance of HSA-AM towards endogenous proteases and its reduced clearance from the blood. HSA-AM may be a promising drug candidate for clinical application.

1 August 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YNYayoi Nishimoto
Yayoi Nishimoto
SNSayaka Nagata
Sayaka Nagata
EAEmiko Akashi
Emiko Akashi
MYMotoo Yamasaki
Motoo Yamasaki
KKKazuo Kitamura
Kazuo Kitamura

1 November 2020 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
EAEmiko Akashi
Emiko Akashi
SNSayaka Nagata
Sayaka Nagata
MYMotoo Yamasaki
Motoo Yamasaki
KKKazuo Kitamura
Kazuo Kitamura
Adrenomedullin (AM) improves colitis in animal models and patients with inflammatory bowel disease. We have developed a PEGylated AM derivative (PEG-AM) for clinical application because AM has a short half-life in the blood. However, modification by addition of polyethylene glycol (PEG) may compromise the function of the original peptide. In this paper, we examined the time course of cAMP accumulation induced by 5 and 60 kDa PEG-AM and compared the activation of calcitonin gene-related peptide (CGRP), AM1 and AM2 receptors by AM, 5 and 60 kDa PEG-AM. We also evaluated the effects of antagonists on the action of 5 and 60 kDa PEG-AM. PEG-AM stimulated cAMP production induced by these receptors; the increase in cAMP levels resulting from application of PEG-AM peaked at 15 min. Moreover, PEG-AM activity was antagonized by CGRP (8–37) or AM (22–52) (antagonists of CGRP and AM receptors, respectively) and the maximal response was not suppressed. These findings indicate that the effects of PEG-AM are similar to those of native AM.